NCT05166876View on ClinicalTrials.gov

Brequinar Combined With Dipyridamole in Patients With Mild to Moderate COVID-19

PHASE2TerminatedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

February 1, 2022

Primary Completion Date

June 4, 2022

Study Completion Date

June 4, 2022

Conditions
COVID-19
Interventions
DRUG

Brequinar Sodium

50 mg, 100 mg, 150 mg, 200 mg x 5 days

DRUG

Dipyridamole 75 MG

75 mg TID for 5 days

DRUG

Placebo

50 mg, 100 mg, 150 mg, 200 mg x 5 days

Trial Locations (7)

395006

Global Hospital, Surat

411013

Noble Hospital, Hadapsar

531011

King George Hospital, Visakhapatnam

532001

RIMS - Government Medical College, Srikakulam

560060

Rajarajeshwari Medical College and Hospital, Bangalore

600123

Panimalar Hospital, Chennai

605006

JIPMER Hospital, Puducherry

Sponsors
All Listed Sponsors
lead

Clear Creek Bio, Inc.

INDUSTRY

NCT05166876 - Brequinar Combined With Dipyridamole in Patients With Mild to Moderate COVID-19 | Biotech Hunter | Biotech Hunter